Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363919 · ClinicalTrials.gov registry record · NA
Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT03363919: Completed NA study, sponsored by Mayo Clinic.
NCT03363919 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03363919, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The Researchers are going to gather information regarding the use of rTMS as a treatment for depression in adolescents with Major Depressive Disorder. The researchers also hope to learn if measures of brain activity (cortical excitability and inhibition) collected with transcranial magnetic stimulation (TMS) can be used to identify which patients will benefit from certain types of rTMS treatment.
Primary Outcome
CDRS-R is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (possible total score from 17 to 113), rated by a clinician via interviews with the child and parent. A score of ≥40 is indicative of depression, whereas a score ≤28 is often used to define remission (minimal or no symptoms)
Interventions
- DEVICE NeuroStar TMS Therapy® System
- DEVICE NeuroStar XPLOR®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2023-03-03 |
| Phase | NA |
What the finished NCT03363919 record still lists
NCT03363919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which NeuroStar TMS Therapy® System is the first listed.
NCT03363919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03363919 about?
NCT03363919 is a clinical study titled "Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression". The Researchers are going to gather information regarding the use of rTMS as a treatment for depression in adolescents with Major Depressive Disorder. The researchers also hope to learn if measures of brain activity (cortical excitability and inhibition) collected with transcranial magnetic stimulat...
What is the current status of trial NCT03363919?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2018-09-24. Estimated completion is 2023-03-03.
What interventions are being tested in trial NCT03363919?
The interventions under investigation include: NeuroStar TMS Therapy® System (DEVICE), NeuroStar XPLOR® (DEVICE).
Who is sponsoring clinical trial NCT03363919?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03363919's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI